Ettinger, S. and Mayer-Ferbas, J. and Jeindl, R. (2025): Enfortumab Vedotin in combination with Pembrolizumab in Urothelial Cancer. Rapid Review Nr.: 019.

Grabenhofer, L. and Giess, D. and Pleyer, J.A. and Hofer, V. (2025): Further Development of the Programme on Preventive Medical Check-Ups in Austria. Risk Scores for Cardiovascular Disease: A Systematic Review. HTA-Projektbericht 170b.

Linton-Romir, N. and Rothschedl, E. and Geiger-Gritsch, S. (2025): Catumaxomab (Korjuny®) for the treatment of malignant ascites. Fact Sheet Nr. 196.

Rothschedl, E. and Geiger-Gritsch, S. (2025): Tislelizumab (Tevimbra®) with platinum-based chemotherapy for the first-line treatment of unresectable, locally advanced or metastatic oesophageal squamous cell carcinoma. Fact Sheet Nr. 198.

Marschik, T. and Rothschedl, E. and Geiger-Gritsch, S. (2025): Datopotamab deruxtecan (Datroway®) for the treatment of unresectable or metastatic hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) breast cancer. Fact Sheet Nr. 210.

Kern, J. and Schönegger, R. (2025): Social Prescribing in Primary Care – Development of an Austrian programme theory based on realist evidence. HTA-Projektbericht 173.

Rothschedl, E. and Linton-Romir, N. (2025): Tislelizumab (Tevimbra®) with chemotherapy for the first-line treatment of HER-2-negative locally advanced unresectable or metastatic gastric/gastroesophageal junction adenocarcinoma. Fact Sheet Nr. 199.

Riegelnegg, M. and Rothschedl, E. (2025): Pembrolizumab (Keytruda®) for the treatment of malignant pleural mesothelioma. Fact Sheet Nr. 202.

Rothschedl, E. and Marschik, T. (2025): Blinatumomab (Blincyto®) monotherapy as part of consolidation therapy for the treatment of adult patients with Philadelphia chromosome-negative (Ph-) CD19-positive B-cell precursor acute lymphoblastic leukaemia (ALL). Fact Sheet Nr. 208.

Rothschedl, E. and Linton-Romir, N. (2025): Tislelizumab (Tevimbra®) with etoposide and platinum chemotherapy for the first-line treatment of extensive-stage small-cell lung cancer. Fact Sheet Nr. 225.

Rothschedl, E. and Wolf, S. (2025): Tislelizumab (Tevimbra®) in combination with gemcitabine and cisplatin for the first-line treatment of recurrent or metastatic nasopharyngeal carcinoma. Fact Sheet Nr. 233.

Rothschedl, E. and Linton-Romir, N. (2025): Tislelizumab (Tevimbra®) with platinum-containing chemotherapy as neoadjuvant treatment and then continued as monotherapy as adjuvant treatment, for the treatment of adult patients with resectable non-small cell lung cancer. Fact Sheet Nr. 241.

Marschik, T. and Rothschedl, E. and Geiger-Gritsch, S. (2025): Lisocabtagene maraleucel (Breyanzi®) for the treatment of adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy. Fact Sheet Nr. 212.

AIHTA Appraisal Board Author Group, HTA Austria (2025): Obecabtagene autoleucel (AUCATZYL®) for the treatment of adult patients with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia. Decision Support Document for the Austrian Appraisal Board 005.

Giess, D. and Mayer-Ferbas, J. (2025): PSA-based screening for early detection of prostate cancer. VU Fact Sheet 01, Wien.

Giess, D. and Mayer-Ferbas, J. (2025): Low-Dose-Computer-Tomography (LDCT) screening for early detection of lung cancer. VU Fact Sheet 02, Wien.

Giess, D. and Mayer-Ferbas, J. (2025): Ultrasound screening for abdominal aortic aneurysm (AAA). VU Fact Sheet 03, Wien.

Hofer, V. and Pleyer, J.A. (2025): Nudging interventions to optimise physician prescribing behaviour. HTA-Projektbericht 168.

Giess, D. and Mayer-Ferbas, J. (2025): Further Development of the Programme on Preventive Health Check-Ups in Austria: Screening for Chronic Kidney Disease – a rapid review on benefits, harms and target populations. HTA-Projektbericht 170c.

Schönegger, R. and Hidaka, Y. (2025): Transition from Child and Adolescent to Adult Mental Health Services: Analysis of International Models and Recommendations for Action for Austria. HTA-Projektbericht 177.

Pleyer, J.A. and Hofer, V. and Grabenhofer, L. (2025): Further Development of the Programme on Preventive Health Check-Ups in Austria: Brief interventions for lifestyle counselling Umbrella review and qualitative survey. HTA-Projektbericht 170a.

AIHTA Appraisal Board Author Group, HTA Austria (2025): Lifileucel (AMTAGVI®) for previously treated unresectable or metastatic melanoma. Decision Support Document for the Austrian Appraisal Board 004.

Hafner, S. and Hidaka, Y. (2025): Digital health technologies for self-identification of the risk of perinatal mental illness. HTA-Projektbericht 167.

Jeindl, R. and Mayer-Ferbas, J. and Ettinger, S. (2025): Telerehabilitation for Movement Support in People with Chronic Back Pain – Rapid Review of Effectiveness. Rapid Review Nr.: 018.

Dannenbring, D. (2025): CAR-T cell therapy: Updated effectiveness and safety results from real-world evidence: A systematic review. HTA-Projektbericht 166.

Wild, C. and Krenn-Maritz, P. and Kampmüller, S. and Polzer, R. (2025): Trauma Care: Teaching Recovery Technique (TRT) to children and adolescent refugees. Systematic Review and Evaluation of Austrian TRT-Programme at AFYA. HTA-Projektbericht 165.

Ettinger, S. and Mayer-Ferbas, J. and Jeindl, R. (2025): Serum eye drops for patients with severe ocular surface disease. Rapid Review Nr.: 017.

Colicchia, A. and Fabian, D. and Grabenhofer, L. and Geiger-Gritsch, S. and Grössmann-Waniek, N. and Malikova, E. and Rothschedl, E. and Sehic, O. and Wild, C. and Wolf, S. and Zechmeister-Koss, I. (2025): Teprotumumab (TEPEZZA®) for moderate-to-severe thyroid eye disease. Decision Support Document for the Austrian Appraisal Board 003.

Colicchia, A. and Fabian, D. and Grabenhofer, L. and Grössmann-Waniek, N. and Malíková, E. and Rothschedl, E. and Sehic, O. and Wild, C. and Wolf, S. and Zechmeister-Koss, I. (2025): Fidanacogene elaparvovec (BEQVEZ®) for the treatment of moderately severe to severe haemophilia B. Decision Support Document for the Austrian Appraisal Board 002.

Hollyoak, R. and Hofer, V. and Nicolopoulos, K. and Cameron, A. (2025): Islet cell transplantation for chronic pancreatitis, type 1 diabetes, with and without kidney transplantation. Decision Support Document 143.

Erdos, J. and Pleyer, J. (2025): Drug-coated balloon catheter for the treatment of urethral strictures. Decision Support Document 144.

Kern, J. and Giess, D. and Erdos, J. (2025): Thermal ablation for early-stage breast cancer: cryoablation, microwave, radiofrequency, high-intensity focused ultrasound, and laser ablation. Decision Support Document 145.

Riegelnegg, M. and Pleyer, J. and Goetz, G. (2025): One-stage matrix-assisted cartilage repair with and without bone marrow aspirate concentrate in the knee. Decision Support Document 146.

Semlitsch, T. and Krenn, C. and Berger, N. (2025): Leadless cardiac pacemakers (Update 2025). Decision Support Document 97/ 3. Update.

Rathbone, J. and Ma, N. and Goetz, G. (2025): Temporary nitinol implantation for the treatment of benign prostatic hyperplasia. Decision Support Document 129/ 1. Update.

Grössmann-Waniek, N. and Wild, C. and Malíková, E. and Wolf, S. and Fabian, D. and Sehic, O. and Zechmeister-Koss, I. (2025): Exagamglogene autotemcel (Exa-cel, Casgevy®) for the treatment of beta-thalassaemia and severe sickle cell disease. Decision Support Document for the Austrian Appraisal Board 001.

AIHTA, HTA Austria (2025): Annual Report 2024.

Mayer-Ferbas, J. and Jeindl, R. (2025): Reimbursement models and pricing of digital health technologies and telemonitoring applications – Rapid scoping review. Rapid Review Nr.: 016.